152 reports of this reaction
2.5% of all DORZOLAMIDE HYDROCHLORIDE reports
#2 most reported adverse reaction
TREATMENT FAILURE is the #2 most commonly reported adverse reaction for DORZOLAMIDE HYDROCHLORIDE, manufactured by Micro Labs Limited. There are 152 FDA adverse event reports linking DORZOLAMIDE HYDROCHLORIDE to TREATMENT FAILURE. This represents approximately 2.5% of all 5,992 adverse event reports for this drug.
Patients taking DORZOLAMIDE HYDROCHLORIDE who experience treatment failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TREATMENT FAILURE is a less commonly reported adverse event for DORZOLAMIDE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to treatment failure, the following adverse reactions have been reported for DORZOLAMIDE HYDROCHLORIDE:
The following drugs have also been linked to treatment failure in FDA adverse event reports:
TREATMENT FAILURE has been reported as an adverse event in 152 FDA reports for DORZOLAMIDE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TREATMENT FAILURE accounts for approximately 2.5% of all adverse event reports for DORZOLAMIDE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience treatment failure while taking DORZOLAMIDE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.